Sinovac Biotech, Ltd.



Quote for Sinovac Biotech, Ltd.

Last Trade:
-
Change:
--
Symbol:
SVA
Status:
-
Listed In:
NASDAQ
P/E:
-
EPS:
-
Market cap:
-
Beta:
-
Open:
-
Prev Close:
-
Capital:
-
Volume:
-
Average vol:
-
Amount:
-
Day's Range:
-
52 week Range:
-
Update:-
Quote Delayed 15 Min.
Currency in USD Time=EDTSVA quote

Summary for Sinovac Biotech, Ltd.

Sinovac Biotech Ltd. (Sinovac) is an integrated biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against infectious diseases. It has developed a portfolio of products, consisting of vaccines against the hepatitis A, hepatitis B and influenza viruses. The Company has a production license for Panflu.1, which was the first approved vaccine against the influenza A H1N1 virus (swine flu). Its pipeline consists of various vaccine candidates in the pre-clinical and clinical development phases in China. The Company's product pipeline also includes human vaccines for Japanese encephalitis, haemophilus influenzae type b (Hib), meningitis, rabies, chickenpox, mumps and rubella that has completed or are in pre-clinical development, and a vaccine for the severe acute respiratory syndrome (SARS), virus that has completed a Phase I clinical trial.